Hemodynamic Response to Device Titration in the Shunted Single Ventricle Circulation - A Patient Cohort Modeling Study by Villa, Chet et al.
Clemson University 
TigerPrints 
Publications Mechanical Engineering 
3-2021 
Hemodynamic Response to Device Titration in the Shunted Single 





Follow this and additional works at: https://tigerprints.clemson.edu/mecheng_pubs 
 Part of the Biomedical Engineering and Bioengineering Commons, and the Mechanical Engineering 
Commons 
TITLE 
Hemodynamic Response to Device Titration in the Shunted Single Ventricle Circulation: 
A Patient Cohort Modeling Study  
 
ABSTRACT 
Clinical outcomes of ventricular assist device (VAD) support for shunted single 
ventricle patients trail the larger population due in part to the challenges in optimizing 
VAD support and balancing systemic and pulmonary circulations.  We sought to 
understand the response to VAD titration in the shunted circulation using a lumped-
parameter network modeling six patient-specific clinical cases.  Hemodynamic data 
from six patients (mean BSA=0.30m2) with a systemic-to-pulmonary shunt was used to 
construct simulated cases of heart failure and hemodynamic response to increasing 
VAD flow from 5 to 10 L/min/m2.  With increasing VAD flow, the pulmonary arterial 
pressure stayed relatively constant in 5 patient cases and increased in one patient case.  
The mean VAD flow needed to attain an AVO2 of 30% was 6.5 +/- 1.2 L/min/m2, which 
is higher than that in the equivalent non-shunted scenario due to the partial diversion of 
flow to the pulmonary circulation.  The hemodynamic responses to VAD support can 
vary significantly between specific patient cases; therefore hemodynamic modeling may 
help guide an individualized approach to perioperative VAD management in the shunted 
single ventricle circulation and to understand the patients who may benefit the most 
from VAD support. 
 
 
How to cite this paper: 
 
Villa C, Zafar F, Lorts A, Kung E. “Hemodynamic Response to Device Titration in 
the Shunted Single Ventricle Circulation: A Patient Cohort Modeling Study”, ASAIO 





AVO2 Arterial-venous O2 saturation difference  
BSA Body surface area 
CapO2 Blood O2 carrying capacity 
ConsO2 O2 consumption 
CO Cardiac output 
Qp/Qs Pulmonary-to-systemic flow ratio 
Qp Pulmonary blood flow 
Qs Systemic blood flow 
RSUC Ventricular suction resistance 
SaO2 Arterial O2 saturation 
SpvO2 Pulmonary vein O2 saturation 
SvO2 Venous O2 saturation 
VAD Ventricular assist device 
  
Introduction 
The number of children supported with ventricular assist devices (VADs), has 
grown significantly over the last two decades.  The percentage of children bridged to 
transplant with a VAD has increased from 13% to 33%.1  Increased VAD utilization has 
led to improved waitlist mortality and improved post-transplant outcomes when 
compared to ECMO.2, 3   
However, improvements in outcome due to increased VAD utilization are not 
uniform across the population of children with heart failure. Patients < 1 year of age and 
those with congenital heart disease are less likely to be bridged to transplant on a VAD 
and only 5-6% of infants with congenital heart disease <1 year of age are bridged to 
transplant with a VAD.1  Decreased device utilization in this cohort is likely driven by 
early experiences with VAD therapy showing increased mortality in small children 
(<10kg), especially those with congenital heart disease, where the mortality rate was 
~70%.4  The mortality rate reached 100% for Stage 1 single ventricle patients supported 
with the Berlin EXCOR.5  
Subsequent maturation of the field, the use of alternate cannulation strategies, 
and the use of paracorporeal continuous flow devices in select patients have resulted in 
marked improvements in survival for small patients and those with congenital heart 
disease.6, 7  While there have been significant improvements in survival, clinical 
outcomes for patients with univentricular physiology continue to trail the larger overall 
cohort.  A recent analysis of the Pediatric Interagency Registry for Mechanical 
Circulatory Support (PediMACS) found that 64% of Stage 1 patients achieved a positive 
outcome.  Adverse clinical outcomes are likely driven in part by the challenges in 
balancing the systemic and pulmonary circulations in patients with shunted physiology, 
and in understanding fundamental concepts including pump selection (size and type) 
and patient management.5  Historically, individual centers have been reticent to 
increase VAD flows due to concerns that increased cardiac output may result in 
pulmonary over-circulation and by reports suggesting that the use of a large for body 
surface area (BSA) EXCOR pump may contribute to stroke risk8 and inadequate VAD 
filling.9  Unfortunately there is no significant literature regarding ramp studies in the 
shunted circulation to help understand the hemodynamic effects of VAD titration and 
help guide patient management. Recently, individual centers have reported successful 
support in Pre-Glenn patients using a management strategy incorporating higher VAD 
flows.10, 11  However, it is unclear whether this approach is broadly generalizable and 
there is no concrete conviction across the clinical community for prescribing higher VAD 
flows to shunted patients and if so the values generally needed to provide adequate 
systemic blood flow without compromising respiratory status through overcirculation and 
elevation of pulmonary artery pressures.  Previous data using mathematical modeling 
underscored the potential pitfalls of VAD support in the setting of shunted physiology, 
however, those assumed a pre-specified device revolutions-per-minute setting and did 
not examine the individual, potentially divergent, hemodynamics for a given patient.12  
Thus, in this study, we employed patient-specific lumped-parameter physiology models 
of VAD therapy to quantify the hemodynamic response to VAD titration in the systemic-
pulmonary shunted circulation. 
Methods 
 The overall flow of the methods (Fig 1) involves creating patient-specific 
computational models that describe VAD-supported heart failure scenarios.  Using the 
blood flow information from these simulation results, we computed O2 related 
parameters for the simulated shunted scenarios, as well as for the trivial case if the 
simulated patient had non-shunted circulations given the resulting CO in each simulated 
scenario.  Finally, we quantified the cardiac indices required to achieve specific levels of 
oxygenation comparing between the shunted and non-shunted scenarios.  The details 
for each component of the methods are described in the sections below.   
VAD Support Hemodynamic Simulations 
The hemodynamics of patient-specific VAD support scenarios were simulated 
according to our previous work.9  Briefly, we started with clinical measurements of six 
systemic-pulmonary shunted single ventricle patients (age: 3-6 month, BSA: 0.26-0.34 
m2) (Table S1) from the Great Ormond Street Hospital, Medical University of South 
Carolina, and University of Michigan.13  Institutional review board study approval was 
obtained for each clinical site with informed consent for data use obtained from the 
participants’ legal guardians.  For each patient, we tuned a lumped-parameter 
physiology model based on the individual patient’s clinical measurements to create the 
pre-support model.14, 15  Once tuning was complete, we set the ventricular contractility to 
zero to simulate heart failure and connected a continuous flow VAD model between the 
ventricle and the aorta to arrive at the VAD supported scenario (Fig 2).  While in clinical 
practice the outflow cannula could be attached to one of several locations near the 
aorta, since the lumped-parameter model is a simplified representation of vasculature, 
these locations each correspond to the aortic node as shown in Fig 2.   
The lumped-parameter model formulation includes implementations that capture 
ventricular suction, suction release, and negative ventricular pressure behaviors.  The 
ventricular suction is relevant to the ventricular collapse induced by a VAD if it attempts 
to draw blood from the ventricle below its reference volume, resulting in a negative 
pressure and collapse.  When these suction events occur, tissue may be drawn into the 
cannula or the septum may be drawn closer to the cannula, both of which can inhibit 
blood flow.16  If complete flow obstruction occurs, the inflow cannula attaches to the 
collapsed ventricular wall; in such a case a “pop off” pressure is needed to overcome 
the negative cannula pressure and release the cannula from the wall.  Finally, the 
pressure-volume relationship of the ventricle has two different regimes depending on 
whether ventricular pressure is positive or negative.  All of these behaviors are captured 
in our physiology model formulation.9 
Due to the similar centrifugal designs of commercially available continuous flow 
VADs, they would produce similar hemodynamics when generating the same pressure 
outputs according to the device-specific HQ curves.  We simulated a range of VAD 
pressure outputs in each patient case resulting in a range of cardiac indexes depending 
on the specific patient physiologies.  For the purposes of the analyses in this study, the 
blood flow serves as the independent variable affecting oxygen related parameters.  
Results are reported across the spectrum of flow up-titration until suction-induced 
ventricular collapse occur in the model (as in patients A and B) where the ventricular 
suction resistance (RSUC) ≥0.04 mmHg.s/ml. 
  
O2 Related Parameter Calculations 
Based on the hemodynamic simulation results, we calculated arterial and venous 
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where Qp, Qs, CO, ConsO2, CapO2, SpvO2, SaO2, and SvO2 are mean values of 
pulmonary blood flow, systemic blood flow, cardiac output, O2 consumption, blood O2 
carrying capacity, pulmonary vein O2 saturation, arterial O2 saturation, and venous O2 
saturation, respectively.  SaO2 and SvO2 are the quantities to be solved.  The blood flow 
related parameters Qp, Qs, and CO are quantities available from the hemodynamic 
simulation results.  SpvO2 is assumed to be 97%.  We estimated the value of CapO2 to 
be 0.151 ml-O2/ml-blood based on previously published hemoglobin O2 carrying 
capacity (1.31 ml-O2/gHb consistently across fetal to adult population) and hemoglobin 
concentration in 3-month old infants (0.115 gHb/ml-blood).17, 18  Finally, we estimated 
the value of ConsO2 using the regression model reported by Seckeler et al.8 for critically 
ill children and adults with congenital heart defects;  since this regression model 
requires patient age and weight as inputs, we used the relationship between BSA and 
weight in children to obtain the patient’s weight estimate from the BSA measurement 
which is available in our clinical data.19  
 Finally, using the O2 Saturation results we calculated the oxygen delivery by 
multiplying Qs by CapO2 and SaO2.   
 
O2 Parameters for the Non-shunted Circulation  
We calculated what the SvO2 and oxygen delivery would be if the simulated 
patient cases had non-shunted circulations given the resulting CO in each simulated 
scenario.  In a non-shunted circulation, SaO2 is equaled to SpvO2, the oxygen delivery 
is CO multiplied by CapO2 and SaO2, and SvO2 is solved from the equation 
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Surplus Cardiac Index 
Comparing the shunted to the non-shunted scenario for each simulated patient, 
we quantified the additional cardiac index required to achieve any specific level of 
desired arterial-venous O2 saturation difference (AVO2).  To perform this direct 
comparison, we first mathematically quantified the cardiac index as a function of AVO2 
by fitting a power equation to relate these two quantities using the simulation results 
from each patient model; this resulted in a total of six functions (one for each simulated 
patient) for the shunted scenario and six functions for the non-shunted scenario.  We 
then used these fitted functions to directly compute the difference between the cardiac 
indexes for the shunted and non-shunted scenarios at different AVO2 levels and defined 
the resulting quantity as the “Surplus Cardiac Index.”     
 
Results 
At any particular CI, the shunted circulation produced lower O2 delivery and 
AVO2 than the non-shunted circulation (Fig 3).  The increase in O2 delivery with 
increasing CI, while linear in both cases, had a shallower slope for the shunted 
compared to the non-shunted circulation (Fig 3A).  The mean VAD flow needed to 
achieve an AVO2 of at least 30% for the shunted-circulation was 6.5 L/min/m2, with a 
standard deviation of 1.2 L/min/m2.   
In terms of hemodynamics, the ratio of pulmonary to systemic flow (Qp/Qs) 
slightly decreased with increasing CI in all patient cases (Fig 4A), while the pulmonary 
arterial pressure stayed relatively constant with changing CI in 5 of the patients (Fig 4B).  
One patient experienced sequential increases in pulmonary arterial pressure as VAD 
flow was titrated.  
To achieve any particular AVO2, the shunted circulation required a “surplus 
cardiac index” (as defined in the Methods section) in all patient cases compared to the 
non-shunted circulation (Fig 5).  This surplus cardiac index is a function of the desired 
AVO2.  At 30% AVO2 the mean and standard deviation of the surplus cardiac index in 
the six simulated patients was 3.07 and 1.16 L/min/m2, respectively.  
 
Discussion 
The early experiences supporting children with shunted single ventricle 
physiology were poor;5 none of the patients with shunt physiology survived.  These poor 
outcomes were theorized to be driven by the difficulty in selecting an appropriate pump 
size for patients with parallel circulation, prominent aortopulmonary blood flow, and the 
challenge of anticoagulating neonates and infants due to developmental hemostasis.20  
Since the initial reports, some strides have been made from adjustments in 
hemodynamic support and anticoagulation management.  The field has rapidly shifted 
toward the use of paracorporeal continuous flow devices in order to offset some of the 
concerns of selecting an appropriate pump size.7  There has also been a rapid shift 
toward the use of direct thrombin inhibitors in infants and children supported with 
paracorporeal VADs.21  While outcomes continue to trail those in patients with non-
shunted physiology, survival has clearly improved over time as recent analysis of the 
PediMACS data showed that 64% of shunted patients achieved a positive outcome.7  
Despite these gains, questions remain about the ability to balance pulmonary blood flow 
and oxygen delivery and there are no significant ramp studies to help inform 
management.11  Thus, while the hemodynamic challenges inherent to the shunted 
circulation have been known for decades, the quantifiable impact of VAD therapy on the 
circulation has not been investigated.   
In the current study, a lumped-parameter model assessed the interactions 
between O2 delivery, VAD flow, pulmonary blood flow, systemic blood flow and 
pulmonary arterial pressures to begin to quantify the impact of VAD therapy in shunted 
physiology. The patient-specific simulations demonstrated that the hemodynamic 
response to increasing VAD flows to ensure adequate oxygen delivery is variable and 
patient-specific. This is notable for patient management in that it helps to define 
plausible and expected device titration needs in the shunted circulation, but also 
because it expands upon the previous work using lumped parameters models in the 
shunted circulation.  Previous modeling suggested a 40% increase in pulmonary artery 
pressure with device implantation, however, it was unclear whether these results are 
universal.22  The current study suggests this pulmonary artery pressure elevation is not 
inevitable and that serial titration of the VAD with concomitant decreases in atrial 
pressure may mitigate this effect in select patients.  
In order to further inform patient management, we also compared the shunted 
and non-shunted circulation. The O2 delivery increases with uptitrating VAD flow in the 
shunted circulation, but at a shallower slope when compared to the non-shunted 
circulation due to partial diversion of flow to the pulmonary vascular bed.  The fact that 
not all of the CI contributes to systemic flow (i.e. O2 delivery) in the shunted circulation 
also results in higher AVO2 at any particular CI suggesting larger increments of device 
uptitration will be needed in order to effectively increase systemic oxygen delivery. 
Compared to the non-shunted circulation, a surplus VAD flow of 3.07 L/min/m2 on 
average was needed to offset pulmonary blood flow and achieve similar tissue oxygen 
delivery at an AVO2 of 30%; however, there was a 40% standard-deviation of this 
surplus flow among patient cases.  The scale of the variation is notable and suggests 
that patient-specific estimates of flow based on physiologic parameters or diagnostics 
(including MRI or existing catheterization) would be valuable especially when selecting 
cannulae and pump sizes. The shallower slope of pulmonary artery pressure associated 
with VAD titration in the shunted circulation is also notable. Providers are often hesitant 
to increase flow in larger increments due to concerns that this will disproportionately 
increase pulmonary artery pressure;12, 22 the current study suggests conservative 
uptitration will provide inadequate systemic oxygen delivery and potentially also result in 
higher pulmonary artery pressures given the majority of patients saw a decrement in 
atrial pressures (and subsequently pulmonary artery pressures) as the devices are 
uptitrated. This point is likely fundamental to understanding which shunted patients may 
benefit from VAD support. In patients where elevated common atrial pressure due to 
ventricular dysfunction drives elevation of pulmonary artery pressure, and who have an 
appropriately restrictive shunt, VAD support provides a means to improve oxygen 
delivery and decrease pulmonary artery pressure. The ability to drop common atrial 
pressures while improving systemic output is likely different from the non-VAD 
supported shunted patient where initiation of inotropic support may increase systemic 
oxygen delivery, but does so at the expense of increases in common atrial pressure due 
to residual systolic dysfunction, diastolic dysfunction, and systemic valve regurgitation. 
Thus, the current modeling approach may help providers accommodate for both 
the increased flow needs at time of implant and understand the hemodynamic effects of 
titration.  This approach may also help to understand the long term hemodynamic 
implications of patient growth on support.  While the variation reported may make 
device titration appear a daunting task, it underscores the utility in using mathematical 
models to help guide initial management.  It also suggests centers should have a low 
threshold to consider hemodynamic ramp studies for any patient not progressing 
clinically.  
The initial modeling work by Di Molfetta et al. demonstrated that while VAD 
support improves systemic blood flow, this may come at the expense of increasing 
pulmonary arterial pressure by 40% or more.12  This clinical scenario is well described 
and has led centers to optimize shunt size and medical management (i.e. low systemic 
vascular resistance state) in order to balance Qp/Qs in an individual patient.23, 24 The 
current study finds that increases in pulmonary arterial pressure are not universal with 
up-titration of VAD flow, but also confirms the well-described challenges of VAD support 
in patients with a minimally restrictive shunt where Qp/Qs is high.  We suspect the latter 
situation is what is occurring in the case of patient F (Fig 4).  Patient F has the highest 
Qp/Qs, implying that their shunt is large for the body size, this then allows more of the 
aortic pressure to translate to the pulmonary artery.  The increases in VAD flow needed 
to ensure adequate systemic blood flow resulted in adverse changes in pulmonary 
artery pressure (>15 mmHg).  In situations that mimic the hemodynamics of patient F, 
alternate methods such as maintaining a low systemic vascular resistance may be 
needed to optimize hemodynamics.  Further studies are needed to help identify patients 
likely to respond in a similar manner (e.g. those with larger shunt to body size ratios) 
and to understand the impact that clinical management approaches such as lowering 
the systemic vascular resistance may have on hemodynamic support.  Patient-specific 
modeling may help define the circumstances where adequate hemodynamics will be 
difficult to achieve even with optimal device titration and medical therapy. This is 
consistent with the literature in the two ventricle circulation where the device 
optimization has become an important part of clinical care due to the discrepant 
physiologic responses to device titration.25, 26   
Limitations 
Our study presents six patient-specific scenarios as example cases to illustrate 
the hemodynamic response at different levels of VAD support.  These cases do not 
represent the comprehensive combinations of physiologic parameters that can 
potentially occur in a patient.  Even though the full range of patient scenarios (e.g. high 
vascular resistance state, significant collateral burden, etc) were not specifically 
included as part of the current simulation and analyses, these circumstances can be 
captured and modeled using the method described and this work is ongoing. This 
further emphasizes the importance of patient-specific assessment and the unique needs 
of each patient.  While there was some variation in the characteristics of the patients in 
the current study, the hemodynamic profile of shunted patients listed for transplant may 
be different.  The clinical data used to construct the model did not originate from 
patients with heart failure, and heart failure was simulated via adjustments of the 
contractility parameter in the computational model. The fact that the model assumes no 
inherent ventricular contribution is worth noting when interpreting the results as any 
residual ventricular ejection would alter the cardiac output.  Aortopulmonary collateral 
flow, shunt anatomy, hematocrit variations, and pulmonary artery anatomy also have 
marked effects on hemodynamics and oxygen delivery; we have not accounted for 
these in the current study and are working to understand the potential impact of these 
factors on patient hemodynamics.  Lastly, future modeling studies can benefit from 
incorporating cardiovascular feedback mechanisms to capture the patient's auto-
regulation response to surgery, VAD titration, and hemodynamic manipulation.27 
Conclusions 
Clinical management of VAD patients involves the unique challenge of needing 
to determine appropriate device titration.  Due to the partial diversion of flow to the 
pulmonary circulation, the mean “surplus VAD flow” in order to achieve systemic oxygen 
delivery similar to that in the non-shunted circulation was >3 L/min/m2.  This needed 
additional flow replenishes the flow diverted by the shunt and therefore can be 
determined via an estimation of pulmonary blood flow.  An increase in VAD flow does 
not necessarily result in dramatic increases in pulmonary arterial pressure and may 
allow decreases in common atrial pressure and improved systemic oxygen delivery.  
These results suggest that for shunted patients on VAD support, prescribing higher 
(compared to non-shunted patients of similar body sizes) VAD flows can be considered 
as a potentially beneficial therapeutic option.  Understanding the quantities and range of 
VAD outputs needed to effectively support patients with a shunted circulation is integral 
to surgical planning and to improving support outcomes in this patient population.  
Larger studies describing the hemodynamics effects across the range of patient 
hemodynamic and anatomic profiles will be valuable to further understand the potential 
hemodynamic effects of VAD support in the shunted circulation. 
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Fig 1. Overall flow diagram of the study methods. 
 
 
Fig 2. Circuit model of the VAD-supported systemic-to-pulmonary shunted circulation.  
Labels “AO” and “RSUC” denote the aortic node and the ventricular suction resistance, 
respectively.  Detailed model formulation is described in reference.9  
 
 
Fig 3. O2 related parameters versus cardiac index for six patient-specific simulated 
cases.  Solid (also black) and dotted (also red) lines represent the systemic-to-
pulmonary shunted, and non-shunted (normal), scenario, respectively. 
 
 
Fig 4. Hemodynamic parameters versus cardiac index for six patient-specific simulated 
cases of systemic-to-pulmonary shunting circulation.   
 
 
Fig 5.  The surplus cardiac index reveals in each patient-specific simulated case the 
additional flow required to achieve the same AVO2 for the systemic-to-pulmonary 
shunted scenario relative to the non-shunted (normal) scenario. 
 
